Title : Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Pub. Date : 2018 May

PMID : 29605720






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Finally, we show that the pan-RAF inhibitor sorafenib is not affected by expression of BRAF deletion variant and effectively synergizes with vemurafenib to block resistant cells, suggesting a possible intervention for this class of mutants. Sorafenib zinc fingers and homeoboxes 2 Homo sapiens